Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
24M
-
Shares change
-
+1.78M
-
Total reported value, excl. options
-
$227M
-
Value change
-
+$17.7M
-
Put/Call ratio
-
0.15
-
Number of buys
-
47
-
Number of sells
-
-28
-
Price
-
$9.45
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2018
101 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q3 2018.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24M shares
of 193M outstanding shares and own 12.41% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.08M shares), PRIMECAP MANAGEMENT CO/CA/ (4.07M shares), Foresite Capital Management IV, LLC (2.68M shares), BlackRock Inc. (2.42M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), EcoR1 Capital, LLC (1.23M shares), MORGAN STANLEY (1.03M shares), BANK OF MONTREAL /CAN/ (910K shares), STATE STREET CORP (583K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (497K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.